GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: APT101 | compound 423 [WO2017100558A1] | compound 52 [PMID: 35594649]
Compound class:
Synthetic organic
Comment: APT-101 (APIE Therapeutics) is an orally bioavailable small molecule that acts as an apelin receptor (APLNR; APJ) agonist [2]. It activates the apelin/apelin receptor pathway to trigger the repair of pulmonary vascular endothelial cell breakdown that drives damage in fibrotic and sclerotic lung diseases [3,5-8].
We obtained the IUPAC descriptor for the molecule from the FDA Orphan Drug register. This chemical structure was first claimed in a patent series from RTI International [4], and is a structure match for compound 52 in [2]. |
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| (S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid |
Synonyms ![]() |
| APT101 | compound 423 [WO2017100558A1] | compound 52 [PMID: 35594649] |
Database Links ![]() |
|
| CAS Registry No. | 2100848-01-7 (source: PubChem) |
| PubChem CID | 129226407 |
| Search Google for chemical match using the InChIKey | HSTYVOXQTWCRDM-KRWDZBQOSA-N |
| Search Google for chemicals with the same backbone | HSTYVOXQTWCRDM |
| UniChem Compound Search for chemical match using the InChIKey | HSTYVOXQTWCRDM-KRWDZBQOSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | HSTYVOXQTWCRDM-KRWDZBQOSA-N |